Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer - 雷速
Written by David Thompson
Published 2026-10-23
Viewed 5 min read
Extending letrozole (Femara) for 5 additional years showed a statistically significant improvement in disease-free survival (DFS) vs placebo in postmenopausal patients with hormone receptor (HR)-positive breast cancer who had completed prior adjuvant... [6224 chars]
Post a comment